Table 3.
Markers of Oxidative Stress and RAS
| Measures | Placebo (n=17) | Febuxostat (n=17) | Febuxostat‐Rasburicase (n=17) | P Value | |||
|---|---|---|---|---|---|---|---|
| ANOVA | Placebo vs Febuxostat | Placebo vs Febuxostat‐Rasburicase | Febuxostat vs Febuxostat‐Rasburicase | ||||
| Allantoin, μmol/L | 0.8±0.1 | 0.4±0.0 | 24.9±1.6 | <0.0001 | 0.003 | <0.0001 | <0.0001 |
| Chlorotyrosine/tyrosine ratio, ×10−5 a | 1.5 (0.3; 5.5) | 1.7 (0.5; 6.7) | 2.0 (0.4; 7.0) | 0.9 | ··· | ··· | ··· |
| Homocitrulline/lysine ratio, ×10−5 | 55.9±2.6 | 54.7±2.6 | 55.3±2.7 | 0.5 | ··· | ··· | ··· |
| Myeloperoxidase activity, mU/mLa | 1.2 (1.0; 1.6) | 1.7 (0.8; 1.9) | 0.5 (0.4; 0.8) | 0.001 | 0.3 | 0.027 | 0.03 |
| Malondialdehyde, μmol/La | 0.3 (0.3; 0.4) | 0.5 (0.3; 0.6) | 0.5 (0.4; 0.7) | 0.001 | 0.001 | 0.006 | 1.0 |
| PRA, ng/mL per ha | 1.1 (1.0; 1.7) | 1.7 (1.1; 2.4) | 1.2 (0.9; 2.0) | 0.2 | ··· | ··· | ··· |
| Renin concentration, pg/mLa | 18.1 (13.0; 21.9) | 22.3 (16.1; 25.5) | 17.6 (12.3; 32.6) | 0.6 | ··· | ··· | ··· |
| Aldosterone, pg/mLa | 52.8 (39.9; 70.3) | 66.8 (29.0; 90.0) | 35.0 (27.0; 54.0) | 0.01 | 1.0 | 0.1 | 0.08 |
| Aldosterone/PRA ratio | 55.3±18.7 | 45.0±7.5 | 37.3±5.7 | 0.048 | 0.5 | 0.049 | 0.9 |
| Aldosterone/renin ratioa | 3.1 (2.5; 4.8) | 2.7 (1.5; 4.3) | 2.3 (1.2; 3.5) | 0.08 | ··· | ··· | ··· |
| Angiotensin II, pg/mLa | 1.8 (1.4; 2.4) | 1.9 (1.4; 2.6) | 1.7 (1.3; 2.3) | 0.007 | 1.0 | 0.3 | 0.02 |
| ACE, pg/mL | 93.8±7.9 | 94.3±7.8 | 88.0±9.3 | 0.4 | ··· | ··· | ··· |
Data are given as mean±SEM or median (quartile 1; quartile 3). ACE indicates angiotensin‐converting enzyme; PRA, plasma renin activity; RAS, renin‐angiotensin system.
a
Not normally distributed.